← Back to Search

Fractional Radiofrequency

All subjects for Acne Scars

N/A
Waitlist Available
Research Sponsored by Venus Concept
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks post-final treatment
Awards & highlights

Study Summary

This study is evaluating whether fractional radiofrequency is safe and effective for the treatment of acne scarring.

Eligible Conditions
  • Acne Scars

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~average of all treatments
This trial's timeline: 3 weeks for screening, Varies for treatment, and average of all treatments for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Subject Satisfaction
Secondary outcome measures
Subject Scale - 5 Point Scale for Treatment Tolerability
Treatment Pain

Trial Design

1Treatment groups
Experimental Treatment
Group I: All subjectsExperimental Treatment1 Intervention
The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Venus Viva MD
2021
N/A
~20

Find a Location

Who is running the clinical trial?

Venus ConceptLead Sponsor
34 Previous Clinical Trials
1,348 Total Patients Enrolled
2 Trials studying Acne Scars
40 Patients Enrolled for Acne Scars
Matthew GronskiStudy DirectorVenus Concept
6 Previous Clinical Trials
160 Total Patients Enrolled
2 Trials studying Acne Scars
40 Patients Enrolled for Acne Scars

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Apr 2025